Cancer care is being transformed by targeted therapy, immunotherapy, personalized medicine, and emerging mRNA-based universal cancer vaccines. Advances in immunotherapeutics and cellular therapies are improving survival rates, while an off-the-shelf mRNA vaccine from the University of Florida is already in human trials.
The FDA has cleared the Onclarity HPV Self-Collection Kit for at-home use, with availability by prescription expected in the coming months. A JAMA Network Open study found 61% of women still prefer clinic screening, while 20% prefer self-sampling at home.
Class action lawsuits allege securities violations by Atara Biotherapeutics and Inovio Pharmaceuticals related to FDA submissions. Atara faces claims over manufacturing issues with its tabelecleucel BLA, while Inovio is accused of misleading statements about INO-3107 regulatory timelines and manufacturing deficiencies.
Australia's National Health and Medical Research Council marks 90 years of funding medical breakthroughs while facing warnings that research institutes could exhaust capital within a decade. The NHMRC's success includes funding the HPV vaccine that put Australia on track to eliminate cervical cancer by 2035, but sustained funding is needed to maintain world-class research capabilities.
Meta-analysis of 23 trials finds neoadjuvant chemoimmunotherapy achieved 66% major pathologic response in head and neck cancer patients compared to 18% for dual-agent and 6% for single-agent immunotherapy, though survival impact remains unclear.
Ten63 Therapeutics announced strategic investment from Chugai Venture Fund and the Gates Foundation, bringing total funding to more than $45 million to advance its BEYOND AI drug discovery platform targeting previously undruggable proteins.
The U.S. FDA granted Breakthrough Therapy Designation for subcutaneous Rybrevant Faspro as monotherapy for adults with advanced head and neck squamous cell carcinoma, based on Phase 1b/2 study data showing rapid and durable responses.
Merck partners with Mayo Clinic in a strategic research and development agreement to apply artificial intelligence and advanced analytics to drug discovery, integrating Mayo Clinic's clinical and genomic datasets with Merck's AI-enabled technologies.
The FDA has approved a monthly dosing schedule for Rybrevant Faspro in EGFR-mutated NSCLC and granted breakthrough therapy designation for the drug as monotherapy in HPV-unrelated recurrent or metastatic head and neck squamous cell carcinoma after prior therapy.
Multiple law firms have filed securities class actions against Inovio Pharmaceuticals after the FDA accepted its INO-3107 BLA for standard rather than accelerated review, following earlier manufacturing delays with the CELLECTRA device.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07768787 |
Validation of Vaginal Self-Sampling With the Abbott Multi-Collect Swab for HPV Screening in Women Aged 30 to 64 Years |
COMPLETED | |
| NCT07657104 |
Developing and Implementing HPV SCREENED |
NOT_YET_RECRUITING | NA |
| NCT07471113 |
Mobile App-Supported HPV and Breast Cancer Awareness Program |
COMPLETED | NA |
| NCT07336134 |
PopSci CHW4CervixHealth |
RECRUITING | NA |
| NCT07259616 |
Incidence of Cervical Cancer in HPV-positive Women With Low-grade Cytological Abnormalities |
COMPLETED | |
| NCT07232355 |
Prevention of Cervical Cancer Using the Genotyping Screening and Same-day Self-sampling |
RECRUITING | |
| NCT07072065 |
Impact Of Intralesional Tuberculin Ppd Injection On Anogenital |
COMPLETED | PHASE2 |
| NCT06786429 |
Managing Hepatitis B (Hep. B) and Human Papilloma Virus (HPV) Related Cancers and Mental Health. |
NOT_YET_RECRUITING | PHASE4 |
| NCT06747390 |
Intratumoral Lidocaine Injection Before Oropharyngeal Cancer Surgery |
RECRUITING | PHASE1 |
| NCT06697964 |
High Resolution Anuscopy Study |
RECRUITING |
